29.29

1.01% -0.29

Collegium Pharmaceutical Inc (COLL)

Overview News Price History Option Chain Financials Discussions Forecast

Collegium Pharmaceutical Inc stock is traded at $29.29, with a volume of 393.22K. It is down -1.01% in the last 24 hours and down -23.83% over the past month. Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Previous Close:

$29.58

Open:

$29.6

24h Volume:

393.22K

Relative Volume:

1.05

Market Cap:

$946.54M

Revenue:

$566.77M

Net Income/Loss:

$48.16M

P/E Ratio:

-79.16

EPS:

-0.37

Net Cash Flow:

$274.29M

1W Performance:

-9.01%

1M Performance:

-23.83%

6M Performance:

-9.82%

1Y Performance:

+16.51%

1-Day Range:

$28.97

$29.78

1-Week Range:

$28.97

$32.18

52-Week Range:

$25.13

$42.29

Collegium Pharmaceutical Inc Stock (COLL) Company Profile

Name

Collegium Pharmaceutical Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

781-713-3699

Address

100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA

Employee

197

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

COLL's Discussions on Twitter

Compare COLL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COLL	29.32	946.54M	566.77M	48.16M	274.29M	-0.37
ZTS	176.41	79.52B	9.15B	2.43B	2.31B	4.92
TAK	13.54	43.13B	30.27B	1.93B	3.45B	0.444
HLN	9.425	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.46	18.56B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.02	15.37B	15.24B	-646.50M	1.88B	1.53

Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-24	Downgrade	Jefferies	Buy → Hold
Aug-25-23	Reiterated	Needham	Buy
May-02-23	Resumed	Jefferies	Buy
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Jul-14-20	Initiated	BWS Financial	Sell
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy
Oct-30-19	Reiterated	Needham	Buy
May-03-19	Resumed	H.C. Wainwright	Buy
Apr-12-19	Resumed	Janney	Buy
Mar-20-19	Initiated	SunTrust	Hold
Jan-16-19	Reiterated	Needham	Buy
Mar-08-18	Reiterated	H.C. Wainwright	Buy
Feb-07-18	Reiterated	Needham	Buy
Dec-05-17	Reiterated	Needham	Buy
Sep-11-17	Initiated	H.C. Wainwright	Buy
May-11-17	Reiterated	Needham	Buy
Sep-13-16	Initiated	Gabelli & Co	Buy
Jun-01-15	Initiated	Jefferies	Buy
Jun-01-15	Initiated	Needham	Buy
Jun-01-15	Initiated	Piper Jaffray	Overweight

View All

Collegium Pharmaceutical Inc Stock (COLL) Latest News

06:34 AM

Amalgamated Bank Has $372,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

06:34 AM

04:53 AM

121,446 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Bought by Empowered Funds LLC - MarketBeat

04:53 AM

04:39 AM

Victory Capital Management Inc. Has $27.46 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

04:39 AM

Nov 14, 2024

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - Simply Wall St

Nov 14, 2024

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Rubric Capital Management LP Adjusts Stake in Collegium Pharmace - GuruFocus.com

Nov 13, 2024

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? - Yahoo Finance

Nov 13, 2024

Nov 12, 2024